News and Announcements
Medication Adherence Platform, MedAdvisor, Lists on the ASX
- Published December 01, 2015 10:46AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
1st December 2015, ASX Announcement
- MedAdvisor raises $5m in oversubscribed public offer
- MedAdvisor commences trading under ticker code MDR
- MedAdvisor announces new medication training relationship with Amgen
MedAdvisor Limited (MedAdvisor or Company) an Australian software developer focused on improving health outcomes by placing patients at the centre of connected health platforms, has been re-admitted to the Australian Securities Exchange. MedAdvisor, trading under the ticker code MDR, commences trading today following a reverse takeover of Exalt Resources Limited (ASX: ERD) by MedAdvisor International Pty Ltd.
The company also announces it has entered a new medication training relationship with Amgen, the world’s largest independent biotechnology company, which currently markets eight products in Australia for the treatment of cancer, kidney disease, bone disease and other serious illnesses.
To read the full announcement, please click here.